Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

ABOS

Acumen Pharmaceuticals Inc

Jan 16 • 04:00PM ET

1.89

+0.03 1.61 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB AVXL SAVA PRTA NBIX AXSM AUPH QURE VYGR CORT

| Held by: VTI VXF IWC DFAC AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.21	Insider Own	22.14%	Shs Outstand	60.57M	Perf Week	4.42%
Market Cap	114.48M	Forward P/E	-	EPS next Y	-1.58	Insider Trans	-1.51%	Shs Float	47.25M	Perf Month	-10.00%
Enterprise Value	18.71M	PEG	-	EPS next Q	-0.45	Inst Own	51.01%	Short Float	1.17%	Perf Quarter	-11.27%
Income	-133.35M	P/S	-	EPS this Y	-19.63%	Inst Trans	-4.53%	Short Ratio	2.60	Perf Half Y	26.00%
Sales	0.00M	P/B	1.23	EPS next Y	22.76%	ROA	-65.18%	Short Interest	0.55M	Perf YTD	-10.43%
Book/sh	1.54	P/C	0.90	EPS next 5Y	7.37%	ROE	-85.93%	52W High	2.46 -23.17%	Perf Year	10.53%
Cash/sh	2.09	P/FCF	-	EPS past 3/5Y	11.81% -54.87%	ROIC	-110.88%	52W Low	0.86 121.03%	Perf 3Y	-66.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.81% 7.58%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-60.99%	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.60	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.02	EPS Q/Q	11.85%	SMA20	-4.80%	Beta	0.23	Target Price	6.40
Payout	-	Debt/Eq	0.33	Sales Q/Q	-	SMA50	-1.33%	Rel Volume	1.43	Prev Close	1.86
Employees	61	LT Debt/Eq	0.29	Earnings	Nov 12 BMO	SMA200	25.29%	Avg Volume	213.33K	Price	1.89
IPO	Jul 01, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	27.03% -	Trades		Volume	305,515	Change	1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	Citigroup	Buy	$4
Jul-26-24	Initiated	Citigroup	Buy	$7
Dec-12-23	Initiated	Deutsche Bank	Buy	$8
Jul-20-23	Resumed	BofA Securities	Buy	$9 → $14
May-18-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jul-15-22	Initiated	BTIG Research	Buy	$15
Jun-30-22	Initiated	H.C. Wainwright	Buy	$15
Jan-21-22	Upgrade	BofA Securities	Neutral → Buy	$16 → $14
Jul-26-21	Initiated	UBS	Buy	$27
Jul-26-21	Initiated	Stifel	Buy	$27
Jul-26-21	Initiated	Credit Suisse	Outperform	$26
Jul-26-21	Initiated	BofA Securities	Neutral	$20

Show Previous Ratings

Dec-02-25 05:54PM	Acumen Pharmaceuticals Presents Results on Alzheimers Disease at Conference (Exec Edge) -7.89% +10.29%
08:00AM	Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
Nov-18-25 08:00AM	Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) +5.06%
Nov-17-25 08:00AM	Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer's Disease (GlobeNewswire) -8.67%
Nov-12-25 04:01PM	Acumen Pharmaceuticals Inc (ABOS) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -7.18%
07:00AM	Loading…
07:00AM	Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Nov-10-25 08:00AM	Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors (GlobeNewswire)
Nov-05-25 04:00PM	Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire) -6.40%
Nov-04-25 04:00PM	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference (GlobeNewswire) -11.01%
Aug-26-25 04:00PM	Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 07:00AM	Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -11.27%
Aug-05-25 04:00PM	Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-28-25 08:00AM	Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025 (GlobeNewswire) -7.01%
Jul-16-25 05:04AM	Acumen and JCR partner on brain delivery therapy for Alzheimers (Pharmaceutical Technology) +5.34%
Jul-15-25 07:00AM	JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimers Disease, Enabled by J-Brain Cargo® Technology Platform (Business Wire) -12.08%
07:00AM	Loading…
07:00AM	Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery Therapy for Alzheimer's Disease (GlobeNewswire)
Jul-10-25 08:00AM	Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC) 2025 (GlobeNewswire)
May-21-25 04:52AM	Philanthropy CEO: Silicon Valley entrepreneurs who think they can cure poverty are a red flag (Fortune)
04:52AM	Acumen CEO: Entrepreneurs who think they can cure poverty with the Silicon Valley model are a red flag (Fortune)
May-14-25 03:06AM	Acumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com) -6.67%
May-13-25 10:30PM	Q1 2025 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-07-25 04:00PM	Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference (GlobeNewswire)
May-06-25 04:00PM	Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
Apr-02-25 07:00AM	Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting (GlobeNewswire)
Apr-01-25 07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-28-25 03:01AM	Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
01:00AM	Q4 2024 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-25 10:05AM	Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript (SeekingAlpha) +6.03%
08:22AM	Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimers (Clinical Trials Arena)
07:00AM	Loading…
07:00AM	Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights (GlobeNewswire)
Mar-26-25 08:00AM	Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease (GlobeNewswire)
Mar-20-25 04:00PM	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 (GlobeNewswire) -7.09%
Mar-19-25 08:00AM	Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers (GlobeNewswire)
Mar-18-25 08:48AM	Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimers (GlobeNewswire)
Mar-12-25 08:00AM	Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-10-25 04:00PM	Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.83%
Jan-10-25 08:05AM	Acumen announces Phase 1 INTERCEPT-AD study publication (TipRanks)
Jan-09-25 08:00AM	Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings (GlobeNewswire)
Nov-26-24 04:00PM	Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -6.78%
Nov-13-24 02:06AM	Acumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) -5.42%
Nov-12-24 10:54PM	Q3 2024 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -16.93%
07:00AM	Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Nov-11-24 04:00PM	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference (GlobeNewswire)
Nov-06-24 04:00PM	Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference (GlobeNewswire) +7.67%
08:00AM	Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality (GlobeNewswire)
Nov-05-24 04:00PM	Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 (GlobeNewswire)
Oct-31-24 08:05AM	Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (GlobeNewswire)
Oct-23-24 08:00AM	Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
Sep-30-24 04:00PM	Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference (GlobeNewswire)
Sep-27-24 07:46AM	Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug (Pharmaceutical Business Review)
Sep-26-24 08:00AM	Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease (GlobeNewswire)
Sep-25-24 04:00PM	Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 (GlobeNewswire)
Sep-03-24 04:00PM	Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference (GlobeNewswire) -10.58%
Aug-13-24 11:26PM	Q2 2024 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +8.20% -9.21%
07:00AM	Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Aug-06-24 04:00PM	Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024 (GlobeNewswire) -7.32%
Jul-29-24 07:00AM	Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease (GlobeNewswire) -5.46%
Jul-28-24 07:30AM	Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC ) 2024 (GlobeNewswire)
Jul-11-24 08:00AM	Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC ) 2024 (GlobeNewswire) +14.41%
Jun-21-24 11:13AM	Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
May-15-24 03:00AM	Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
02:06AM	Q1 2024 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 11:53AM	ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) +9.82%
07:00AM	Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-13-24 04:00PM	Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
10:15AM	Arthur J. Gallagher Acquires Acumen Advisors (MT Newswires)
May-08-24 05:47PM	Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference (GlobeNewswire)
03:32PM	Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study (MT Newswires)
08:00AM	Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease (GlobeNewswire)
May-07-24 04:00PM	Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024 (GlobeNewswire) -5.62%
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-16-24 08:00AM	Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Apr-08-24 05:38PM	13 Best Penny Stocks to Buy According to Billionaire Ken Griffin (Insider Monkey)
Apr-04-24 02:12PM	Acumen Pharmaceuticals Collaborates with Lonza For Alzheimers Treatment (Exec Edge)
08:00AM	Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease (GlobeNewswire)
Apr-03-24 08:38AM	Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick (Zacks)
Mar-28-24 12:00PM	Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-27-24 09:46AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.33%
Mar-26-24 09:20PM	Q4 2023 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -11.76%
11:52AM	ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights (GlobeNewswire)
Mar-21-24 10:41AM	Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-19-24 04:00PM	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024 (GlobeNewswire)
Mar-18-24 10:31AM	15 Best Anti-Aging Foods for Youthful Skin (Insider Monkey)
Mar-12-24 04:00PM	Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days (GlobeNewswire) +5.58%
Mar-08-24 08:50AM	Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD 2024 Annual Meeting (GlobeNewswire)
Feb-29-24 09:40AM	Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-21-24 08:00AM	Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD 2024 Annual Meeting (GlobeNewswire)
Feb-01-24 07:00AM	Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer (GlobeNewswire)
Jan-30-24 02:14PM	Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot (InvestorPlace)
Jan-24-24 01:58PM	3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom (InvestorPlace)
Jan-04-24 04:15PM	Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-14-23 08:53AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 11:08PM	Q3 2023 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
10:54AM	Acumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business Update (GuruFocus.com)
09:31AM	Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? (PR Newswire)
07:00AM	Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures (GlobeNewswire)

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zuga Matt	CFO & Chief Business Officer	Jan 08 '26	Sale	1.82	6,888	12,513	209,951	Jan 12 06:52 PM
Barton Russell	Chief Operating Officer	Jan 08 '26	Sale	1.86	3,530	6,562	123,269	Jan 12 06:52 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 08 '26	Sale	1.82	36,911	67,246	97,548	Jan 12 06:51 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 12 '26	Sale	1.71	8,548	14,658	83,800	Jan 12 06:51 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 09 '26	Sale	1.76	5,200	9,169	92,348	Jan 12 06:51 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 09 '26	Sale	1.76	12,941	22,832	598,898	Jan 12 06:50 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 08 '26	Sale	1.82	8,143	14,815	611,839	Jan 12 06:50 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 12 '26	Sale	1.73	5,388	9,307	593,510	Jan 12 06:50 PM
Meisner Derek M	Officer	Jan 12 '26	Proposed Sale	1.71	8,548	14,658		Jan 12 04:03 PM
OConnell Daniel Joseph	Officer	Jan 12 '26	Proposed Sale	1.73	5,388	9,307		Jan 12 04:02 PM
Doherty James J.	President and CDO	Jan 08 '26	Sale	1.82	6,467	11,769	54,033	Jan 09 04:39 PM
Doherty James J.	President and CDO	Jan 07 '26	Sale	1.99	1,700	3,379	60,500	Jan 09 04:39 PM
Schacterle Amy	Chief Regulatory Officer	Jan 07 '26	Sale	1.98	1,097	2,176	7,703	Jan 09 04:38 PM
Meisner Derek M	Officer	Jan 09 '26	Proposed Sale	1.76	5,200	9,169		Jan 09 04:22 PM
OConnell Daniel Joseph	Officer	Jan 09 '26	Proposed Sale	1.76	12,941	22,832		Jan 09 04:20 PM
Doherty James J.	Officer	Jan 08 '26	Proposed Sale	1.82	6,467	11,769		Jan 08 05:15 PM
Meisner Derek M	Officer	Jan 08 '26	Proposed Sale	1.82	36,911	67,244		Jan 08 05:02 PM
Barton Russell	Officer	Jan 08 '26	Proposed Sale	1.86	3,530	6,562		Jan 08 04:49 PM
Zuga Matt	Officer	Jan 08 '26	Proposed Sale	1.82	6,888	12,513		Jan 08 04:34 PM
OConnell Daniel Joseph	Officer	Jan 08 '26	Proposed Sale	1.82	8,143	14,815		Jan 08 04:31 PM
Zuga Matt	CFO & Chief Business Officer	Jan 07 '26	Sale	1.99	5,805	11,566	216,839	Jan 07 09:31 PM
Zuga Matt	CFO & Chief Business Officer	Jan 06 '26	Sale	1.97	5,100	10,028	222,644	Jan 07 09:31 PM
Zuga Matt	CFO & Chief Business Officer	Jan 05 '26	Sale	1.96	4,000	7,842	227,744	Jan 07 09:31 PM
Siemers Eric	Chief Medical Officer	Jan 06 '26	Sale	1.97	6,834	13,442	159,464	Jan 07 09:31 PM
Siemers Eric	Chief Medical Officer	Jan 05 '26	Sale	1.96	4,000	7,835	166,298	Jan 07 09:31 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 07 '26	Sale	1.99	37,755	74,981	619,982	Jan 07 09:31 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 06 '26	Sale	1.97	5,102	10,032	657,737	Jan 07 09:31 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 05 '26	Sale	1.97	4,649	9,163	662,839	Jan 07 09:31 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 07 '26	Sale	1.99	11,770	23,414	134,459	Jan 07 09:30 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 06 '26	Sale	1.97	10,898	21,438	146,229	Jan 07 09:30 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 05 '26	Sale	1.96	4,000	7,838	157,127	Jan 07 09:30 PM
Barton Russell	Chief Operating Officer	Jan 05 '26	Sale	1.96	4,000	7,832	132,117	Jan 07 09:30 PM
Barton Russell	Chief Operating Officer	Jan 06 '26	Sale	1.97	3,618	7,114	128,499	Jan 07 09:30 PM
Barton Russell	Chief Operating Officer	Jan 07 '26	Sale	1.99	1,700	3,378	126,799	Jan 07 09:30 PM
Schacterle Amy	Officer	Jan 07 '26	Proposed Sale	1.98	1,097	2,176		Jan 07 05:16 PM
Doherty James J.	Officer	Jan 07 '26	Proposed Sale	1.99	1,700	3,380		Jan 07 05:11 PM
Meisner Derek M	Officer	Jan 07 '26	Proposed Sale	1.99	11,770	23,415		Jan 07 05:08 PM
Barton Russell	Officer	Jan 07 '26	Proposed Sale	1.99	1,700	3,378		Jan 07 05:01 PM
Zuga Matt	Officer	Jan 07 '26	Proposed Sale	1.99	5,805	11,566		Jan 07 04:58 PM
OConnell Daniel Joseph	Officer	Jan 07 '26	Proposed Sale	1.99	37,755	74,981		Jan 07 04:49 PM
Meisner Derek M	Officer	Jan 06 '26	Proposed Sale	1.97	10,898	21,438		Jan 06 04:59 PM
Siemers Eric	Officer	Jan 05 '26	Proposed Sale	1.97	6,834	13,443		Jan 06 04:50 PM
Barton Russell	Officer	Jan 06 '26	Proposed Sale	1.97	3,618	7,114		Jan 06 04:47 PM
Zuga Matt	Officer	Jan 06 '26	Proposed Sale	1.97	5,100	10,028		Jan 06 04:43 PM
OConnell Daniel Joseph	Officer	Jan 06 '26	Proposed Sale	1.97	5,102	10,031		Jan 06 04:40 PM
Meisner Derek M	Officer	Jan 05 '26	Proposed Sale	1.96	4,000	7,838		Jan 05 05:17 PM
Siemers Eric	Officer	Jan 05 '26	Proposed Sale	1.96	4,000	7,835		Jan 05 05:09 PM
Barton Russell	Officer	Jan 05 '26	Proposed Sale	1.96	4,000	7,832		Jan 05 05:06 PM
Zuga Matt	Officer	Jan 05 '26	Proposed Sale	1.96	4,000	7,842		Jan 05 05:03 PM
OConnell Daniel Joseph	Officer	Jan 05 '26	Proposed Sale	1.97	4,649	9,163		Jan 05 04:48 PM
Zuga Matt	CFO & Chief Business Officer	Jan 23 '25	Sale	1.72	28,902	49,633	231,744	Jan 23 09:19 PM
Zuga Matt	CFO & Chief Business Officer	Jan 21 '25	Sale	1.60	4,364	6,986	260,646	Jan 23 09:19 PM
OConnell Daniel Joseph	Chief Executive Officer	Jan 21 '25	Sale	1.59	12,619	20,102	667,488	Jan 23 05:18 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 21 '25	Sale	1.59	3,418	5,435	161,127	Jan 23 05:16 PM
Barton Russell	Chief Operating Officer	Jan 21 '25	Sale	1.61	2,914	4,692	136,117	Jan 23 05:14 PM
Siemers Eric	Chief Medical Officer	Jan 21 '25	Sale	1.59	3,219	5,118	170,298	Jan 23 05:06 PM
Zuga Matt	Officer	Jan 23 '25	Proposed Sale	1.72	28,902	49,633		Jan 23 04:17 PM
Meisner Derek M	Officer	Jan 21 '25	Proposed Sale	1.59	3,418	5,435		Jan 21 04:32 PM
Siemers Eric	Officer	Jan 21 '25	Proposed Sale	1.59	3,219	5,118		Jan 21 04:31 PM
Barton Russell	Officer	Jan 21 '25	Proposed Sale	1.70	2,914	4,962		Jan 21 04:29 PM
Zuga Matt	Officer	Jan 21 '25	Proposed Sale	1.60	4,364	6,986		Jan 21 04:25 PM
OConnell Daniel Joseph	Officer	Jan 21 '25	Proposed Sale	1.59	12,619	20,109		Jan 21 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABOS

Acumen Pharmaceuticals Inc

Upgrade your FINVIZ experience